N-terminal polypeptide derived from vMIP-II exerts its antitumor activity by inhibiting the CXCR4 pathway in human glioma

Yang,Qingling; Wu,Haihua; Wang,Haifeng; Li,Yu; Zhang,Lingyu; Zhu,Lihua; Wang,Wenrui; Zhou,Jihong; Fu,Yingxiao; Chen,Sulian; Wu,Qiong; Chen,Changjie; Zhou,Congzhao

doi:10.3892/ijo.2017.3906

N-terminal polypeptide derived from vMIP-II exerts its antitumor activity by inhibiting the CXCR4 pathway in human glioma

Authors:
- Qingling Yang
- Haihua Wu
- Haifeng Wang
- Yu Li
- Lingyu Zhang
- Lihua Zhu
- Wenrui Wang
- Jihong Zhou
- Yingxiao Fu
- Sulian Chen
- Qiong Wu
- Changjie Chen
- Congzhao Zhou
View Affiliations

Affiliations: Hefei National Laboratory for Physical Sciences at Microscale and the Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, P.R. China, Clinical Testing and Diagnose Experimental Center of Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Biotechnology, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Biochemistry and Molecular Biology, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Bioscience, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233030, P.R. China
Published online on: March 8, 2017 https://doi.org/10.3892/ijo.2017.3906
Pages: 1160-1174
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emerging evidence demonstrates that the stromal derived factor-1 (SDF-1α)/CXCR4 axis is associated with tumor aggressiveness and metastasis, including glioma, the most common brain cancer. In the present study, we demonstrated that a novel designed peptide NT21MP of viral macrophage inflammatory protein II, targeting CXCR4 inhibits SDF-1α-induced activation in glioma. The effects of NT21MP on CXCR4 expression, cell survival and migration were assessed on the human glioma cell line U251 and SHG-44 exposed to SDF-1α, by western blotting, MTT assay, flow cytometry and transwell migration assay. Our results illustrated that NT21MP inhibited SDF-1α induced proliferation, migration and invasion by upregulated pro-apoptotic genes (Bak1 and caspase-3) and downregulated Bcl-2/Bax as well as cell cycle regulators (cyclin D1 and CDK4) to arrest cell cycle in G0/G1 phase and promote apoptosis. By RT-qPCR and immunofluorescence we found that CXCR4 was highly expressed in SHG-44 cells. Our results from wound healing and transwell invasion assays indicated silencing of CXCR4 significantly inhibited the SDF-1α‑induced migration and invasion; similarly, flow cytometry showed that treatment with si-CXCR4 affected cell cycle and induced cell apoptosis in SHG-44. However, these effects were significantly weakened by NT21MP. In conclusion, the present study indicates that NT21MP plays a regulatory role in the SDF-1α/CXCR4 axis and further manages the invasion, migration, apoptosis and cell cycle of glioma cells. Thus, NT21MP might represent a novel therapeutic approach against glioma.

View Figures

View References

1	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
2	Fishman M and Seigne J: Immunotherapy of metastatic renal cell cancer. Cancer Control. 9:293–304. 2002.PubMed/NCBI
3	Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev. 13:143–154. 2002. View Article : Google Scholar : PubMed/NCBI
4	Li W and Graeber MB: The molecular profile of microglia under the influence of glioma. Neuro Oncol. 14:958–978. 2012. View Article : Google Scholar : PubMed/NCBI
5	Flüh C, Hattermann K, Mehdorn HM, Synowitz M and Held-Feindt J: Differential expression of CXCR4 and CXCR7 with various stem cell markers in paired human primary and recurrent glioblastomas. Int J Oncol. 48:1408–1416. 2016.PubMed/NCBI
6	Cho KS, Yoon SJ, Lee JY, Cho NH, Choi YD, Song YS and Hong SJ: Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model. Oncol Lett. 6:933–938. 2013.PubMed/NCBI
7	Maddirela DR, Kesanakurti D, Gujrati M and Rao JS: MMP-2 suppression abrogates irradiation-induced microtubule formation in endothelial cells by inhibiting αvβ3-mediated SDF-1/CXCR4 signaling. Int J Oncol. 42:1279–1288. 2013.PubMed/NCBI
8	Sekuła M, Miekus K and Majka M: Downregulation of the CXCR4 receptor inhibits cervical carcinoma metastatic behavior in vitro and in vivo. Int J Oncol. 44:1853–1860. 2014.
9	Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, et al: Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 201:1307–1318. 2005. View Article : Google Scholar : PubMed/NCBI
10	Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E and Alizon M: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol. 72:6381–6388. 1998.PubMed/NCBI
11	Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS and Heveker N: AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 75:1240–1247. 2009. View Article : Google Scholar : PubMed/NCBI
12	Khan A, Greenman J and Archibald SJ: Small molecule CXCR4 chemokine receptor antagonists: Developing drug candidates. Curr Med Chem. 14:2257–2277. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, Power CA, Lüttichau HR, Gerstoft J, Clapham PR, et al: A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 277:1656–1659. 1997. View Article : Google Scholar : PubMed/NCBI
14	Yang QL, Ding YQ, Chen CJ, Tang J, Zhang J and Yang ZF: Suppression of murine breast cancer metastasis by selective inhibition of CXCR4 by synthetic polypeptide derived from viral macrophage inflammatory protein II. Chin Sci Bull. 55:2152–2159. 2010. View Article : Google Scholar
15	Yang Q, Chen C, Yang Z, Gao Y and Tang J: Suppression of breast cancer proliferation and induction of apoptosis via AKT and ERK1/2 signal transduction pathways by synthetic polypeptide derived from viral macrophage inflammatory protein II. J Huazhong Univ Sci Technolog Med Sci. 31:497–503. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yang QL, Ding YX, Chen CJ, Yang ZF and Gao YJ: The mechanism of polypeptide derived from viral macrophage inflammatory protein II modulates SDF-1α/CXCR4-induced migration. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:137–140. 2012.In Chinese. PubMed/NCBI
17	Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG and Walenkamp AM: A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 49:219–230. 2013. View Article : Google Scholar
18	Epstein RJ: The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer. 4:901–909. 2004. View Article : Google Scholar : PubMed/NCBI
19	Portella L, Vitale R, De Luca S, D'Alterio C, Ieranò C, Napolitano M, Riccio A, Polimeno MN, Monfregola L, Barbieri A, et al: Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One. 8:e745482013. View Article : Google Scholar : PubMed/NCBI
20	Berghuis D, Schilham MW, Santos SJ, Savola S, Knowles HJ, Dirksen U, Schaefer KL, Vakkila J, Hogendoorn PC and Lankester AC: The CXCR4-CXCL12 axis in Ewing sarcoma: Promotion of tumor growth rather than metastatic disease. Clin Sarcoma Res. 2:24–32. 2012. View Article : Google Scholar : PubMed/NCBI
21	Peled A, Wald O and Burger J: Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 21:341–353. 2012. View Article : Google Scholar : PubMed/NCBI
22	Skommer J, Wlodkowic D and Pelkonen J: CXCR4 expression during tumour cell death. Leuk Res. 31:1155–1156. 2007. View Article : Google Scholar
23	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR 4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
24	Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T and Schettini G: Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 63:1969–1974. 2003.PubMed/NCBI
25	Tu H, Zhou Z, Liang Q, Li Z, Li D, Qing J, Wang H and Zhang L: CXCR4 and SDF-1 production are stimulated by hepatocyte growth factor and promote glioma cell invasion. Onkologie. 32:331–336. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ehtesham M, Winston JA, Kabos P and Thompson RC: CXCR4 expression mediates glioma cell invasiveness. Oncogene. 25:2801–2806. 2006. View Article : Google Scholar : PubMed/NCBI
27	Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 294:173–177. 2001. View Article : Google Scholar : PubMed/NCBI
28	Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, Kawauchi J, Sunamori M, Marumo F, Kitajima S, et al: Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res. 92:9–12. 2003. View Article : Google Scholar
29	Chen S, Zhu L, Huang J, Cai Y, Lu X, Yang Q, Wu Q, Chen C and Wang Z: Arsenic trioxide targets miR-125b in glioma cells. Curr Pharm Des. 20:5354–5361. 2014. View Article : Google Scholar : PubMed/NCBI
30	Middeldorp J and Hol EM: GFAP in health and disease. Prog Neurobiol. 93:421–443. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhou J, Liu Q, Wang J, Guo X and Song L: Expressions of peroxiredoxin 1, peroxiredoxin 6 and GFAP in human brain astrocytoma and their clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 32:1255–1259. 2012.In Chinese. PubMed/NCBI
32	Sehgal A, Keener C, Boynton AL, Warrick J and Murphy GP: CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol. 69:99–104. 1998. View Article : Google Scholar : PubMed/NCBI